+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Asia-Pacific Metabolic Disorder Therapeutics Market 2020-2026

  • ID: 5241079
  • Report
  • November 2020
  • Region: Asia Pacific
  • Orion Market Research Private Limited
UP TO OFF
until Dec 31st 2021
1 of 3

FEATURED COMPANIES

  • Astellas Pharma, Inc.
  • Biocon, Ltd.
  • Cipla, Inc.
  • Lupin, Ltd.
  • MORE
Asia-Pacific Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report, By Therapy (Drug Therapy, Gene Therapy, Cellular Transplantation, Enzyme Replacement Therapy, and Others), By Disease (Obesity, Diabetes, Lysosomal Storage Disease, Hypercholesterolemia, and Others), and Forecast, 2020-2026.

Asia-Pacific metabolic disorder therapeutics market is estimated to grow at a CAGR of 8.2% during the forecast period. The rising prevalence of metabolic disorders and increasing awareness regarding health is driving the demand for metabolic disorder therapeutics in the region. As per the World Bank, in China, the prevalence of diabetes among the population ages 20-79 was 9.2% in 2019. It is growing significantly due to sedentary lifestyle habits. In India, the prevalence of diabetes was found to be 11.8% in people above the age of 50.

Diabetes disrupts normal metabolism, which results in the demand for medications that are used for the treatment of the condition. These medications include Metformin (Glucophage, Glumetza, others), Thiazolidinediones (rosiglitazone (Avandia), and pioglitazone (Actos)), and others. Rosiglitazone (Avandia) is intended for use as an adjunct to exercise and diet to improve glycemic control in adults suffering from type 2 diabetes mellitus. It is a highly potent and selective agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ)-responsive genes that participate in the regulation of fatty acid metabolism.

Asia-Pacific metabolic disorder therapeutics market is segmented based on type and disease. Based on type, the market is classified into drug therapy, gene therapy, cellular transplantation, enzyme replacement therapy, and others. Drug therapy is being significantly preferred for the treatment of metabolic disorders. Pioglitazone (Actos) and Metformin (Glucophage) are some common metabolic drugs that are used for the treatment of the metabolic syndrome. Based on disease, the market is classified into obesity, diabetes, lysosomal storage disease, hypercholesterolemia, and others.

Some prominent players in the market include Lupin Ltd., Shanghai Fosun Pharmaceutical Group (Co.) Ltd., AstraZeneca plc, and Cipla Inc. Product launches and partnerships and collaborations have been reported significantly in the market. For instance, in February 2020, AstraZeneca India declared the launch of Qtern (Dapagliflozin 10mg + Saxagliptin 5mg film Coated Tablets) to treat type 2 diabetes. It is indicated as an adjunct to exercise and diet for improvement of glycemic control in adults with type 2 diabetes mellitus. This oral medication aims to improve blood sugar levels with a significantly low risk of hypoglycemia.

Research Methodology

The market study of the Asia-Pacific metabolic disorder therapeutics market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. the team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

1. Asia-Pacific Metabolic Disorder Therapeutics Market Research and Analysis by Therapy
2. Asia-Pacific Metabolic Disorder Therapeutics Market Research and Analysis by Disease

The Report Covers:
  • Comprehensive research methodology of the Asia-Pacific metabolic disorder therapeutics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Asia-Pacific metabolic disorder therapeutics market.
  • Insights about market determinants which are stimulating the Asia-Pacific metabolic disorder therapeutics market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Astellas Pharma, Inc.
  • Biocon, Ltd.
  • Cipla, Inc.
  • Lupin, Ltd.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Country

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. Asia-Pacific Metabolic Disorder Therapeutics Market by Therapy
5.1.1. Drug Therapy
5.1.2. Gene Therapy
5.1.3. Cellular Transplantation
5.1.4. Enzyme Replacement Therapy
5.1.5. Others
5.2. Asia-Pacific Metabolic Disorder Therapeutics Market by Disease
5.2.1. Obesity
5.2.2. Diabetes
5.2.3. Lysosomal Storage Disease
5.2.4. Hypercholesterolemia
5.2.5. Others

6. Regional Analysis
6.1. China
6.2. India
6.3. Japan
6.4. Rest of Asia-Pacific

7. Company Profiles
7.1. Astellas Pharma, Inc.
7.2. Biocon, Ltd.
7.3. Cipla, Inc.
7.4. Dr. Reddy's Laboratories, Ltd.
7.5. Hengrui Therapeutics, Inc.
7.6. Lupin, Ltd.
7.7. Shanghai Fosun Pharmaceutical Group (Co.), Ltd.
7.8. Shanghai Pharmaceuticals Holding Co., Ltd.
7.9. Sun Pharmaceutical Industries, Ltd.
7.10. Takeda Pharmaceutical Co., Ltd.
Note: Product cover images may vary from those shown
3 of 3
  • Astellas Pharma, Inc.
  • Biocon, Ltd.
  • Cipla, Inc.
  • Dr. Reddy's Laboratories, Ltd.
  • Hengrui Therapeutics, Inc.
  • Lupin, Ltd.
  • Shanghai Fosun Pharmaceutical Group (Co.), Ltd.
  • Shanghai Pharmaceuticals Holding Co., Ltd.
  • Sun Pharmaceutical Industries, Ltd.
  • Takeda Pharmaceutical Co., Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll